In a recent study by Diamandis et al., a global proteomic analysis of meningioma patient cohort of nearly 60 patient FFPE blocks were analyzed and many of the biomarkers that were validated in our current study namely SELENBP1, NDRG1, and MAPK3 were found aberrated in the FFPE samples indicating their true potential as markers for meningiomas that can even be used in clinics (10). This evidence concerns the gene MAPK3 and meningioma.